Summer Street Research Partner, Novenber 15, 2012

[Anonymous]

Probably did have a good quarter. There seems to be no evidence to the contrary.

It remains to be seen if a good early announcement of revenues would offset what another poster said about the 2nd week of January. If he is correct when he said either signed deals or perp walks in the 2nd week of January, either one of those options could resonate with shareholders and potential business partners or suitors.

doubt a good quarter would offset that if that comes to fruition. even a qualified pr person couldnt put lipstick on that.

 

[Anonymous]

Nothing is happening in the 2nd week of January. You will be wrong on this "conspircacy" like all the rest of your silly "theories".

 

[Anonymous]

Thanks for your comparison of Provenge to Herceptin. Very helpful.

 

[Anonymous]

The Zytiga - Provenge data that came out at ASCO two weeks ago show the 2 drugs work together well. Also it was shown that Provenge reduces pain in PC patients. The research report shown in post #1 has turned out to be spot on. Thanks for sharing.

 

[Anonymous]

Have you heard about the case where the provenge-xtandi combination treatment completely cured an advanced prostate cancer patient. The drug synergy may well turn out to be terrific. Here is the Journal of Urology Abstract from last month:


Urology. 2013 Feb;81(2):381-3. doi: 10.1016/j.urology.2012.10.044.

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.

Graff JN, Drake CG, Beer TM.
Abstract

OBJECTIVE:

To describe the case of a patient with castration-resistant, metastatic prostate cancer who achieved a complete and durable biochemical response after treatment with sipuleucel-T while continuing with enzalutamide and to explore the immunologic basis for such a response.

MATERIALS AND METHODS:

We obtained serial prostate-specific antigen (PSA) measurements and bone scans to assess the patient's response to enzalutamide followed by the addition of sipuleucel-T. Using preclinical and clinical data, we describe his response through known immunobiologic mechanisms.

RESULTS:

This patient's PSA level became undetectable during treatment with enzalutamide and began to increase again after 14 months. He opted for treatment with sipuleucel-T, while continuing with the enzalutamide. This resulted in another complete PSA response 6 months after exposure to sipuleucel-T.

CONCLUSION:

Sipuleucel-T typically does not produce significant PSA reductions, and, to the best of our knowledge, only 1 previous report of a durable complete PSA response in a patient with metastatic disease has been published. The timing of this response supports an immune mechanism. The biologic rationale for the combination, coupled with the clinical result observed in our patient, provides a basis for studies of the combination of sipuleucel-T and enzalutamide.

 

[Anonymous]

Wow, that kind of drug synergy between xtandi and provenge would be a total goldmine.